F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.
Citations
333 citations
Cites methods from "F-18 labelled PSMA-1007: biodistrib..."
...PSMA Immunhistochemistry PSMA immunohistochemistry was performed with a series of tissue bank samples from salivary glands, kidneys, and prostate cancer using a standard protocol analogous to the detailed description in a previous publication (15)....
[...]
326 citations
Cites background from "F-18 labelled PSMA-1007: biodistrib..."
..., 18F-PSMA1007), the spleen is recommended instead of the liver for comparison against blood-pool and salivary gland uptake (36)....
[...]
238 citations
213 citations
Cites background from "F-18 labelled PSMA-1007: biodistrib..."
...One new candidate is 18F-PSMA-1007, which exhibits rapid blood clearance but only minimal amounts of activity excreted via the urinary tract (11)....
[...]
...Thus, there has been interest in the development of 18F-labeled PSMA compounds (10,11)....
[...]
200 citations
Additional excerpts
...This compound also takes advantage of the intrinsic positive characteristics (18)F and has been found to identify very small sites of PCa, while also having relatively low urinary excretion, which may aid visualization of intraprostatic or locally recurrent disease [61, 62]....
[...]
References
1,741 citations
1,265 citations
1,169 citations
868 citations
"F-18 labelled PSMA-1007: biodistrib..." refers background in this paper
...All patients had newly diagnosed high-risk prostate cancer (median PSAlevel 14 ng/ml; range 5.8–87.3 ng/ml) with a median age of 65 years (range 55–77) and underwent 18F-PSMA1007 PET/CT imaging 1 and 3 h post injection....
[...]
...Taking into account his normal PSA-value and an increased CRP and BSR (blood sedimentation rate), this finding implies the potential of false-positive uptake in inflammatory activated lymph nodes....
[...]
...5 a: Patient 2, a 72-year-old patient (PSA 15 ng/ml) diagnosed with Gleason 9 (5 + 4) prostate cancer....
[...]
...To determine initial dosimetry, three healthy volunteers (normal PSA) underwent 18F-PSMA-1007 PET/CT with scans obtained at multiple time points up to 6 h p.i....
[...]
...sites of biochemical recurrence (BCR) were localized in 90 % of patients including those with modest elevations in prostate specific antigen (PSA) [1, 2]....
[...]
848 citations
"F-18 labelled PSMA-1007: biodistrib..." refers background in this paper
...All patients had newly diagnosed high-risk prostate cancer (median PSAlevel 14 ng/ml; range 5.8–87.3 ng/ml) with a median age of 65 years (range 55–77) and underwent 18F-PSMA1007 PET/CT imaging 1 and 3 h post injection....
[...]
...Taking into account his normal PSA-value and an increased CRP and BSR (blood sedimentation rate), this finding implies the potential of false-positive uptake in inflammatory activated lymph nodes....
[...]
...5 a: Patient 2, a 72-year-old patient (PSA 15 ng/ml) diagnosed with Gleason 9 (5 + 4) prostate cancer....
[...]
...To determine initial dosimetry, three healthy volunteers (normal PSA) underwent 18F-PSMA-1007 PET/CT with scans obtained at multiple time points up to 6 h p.i....
[...]
...sites of biochemical recurrence (BCR) were localized in 90 % of patients including those with modest elevations in prostate specific antigen (PSA) [1, 2]....
[...]